NACHO was formed in July 2014 by clinicians and scientists from twelve institutions dedicated to developing a research infrastructure to effectively implement clinical and translational studies and conduct biological research of histiocytic diseases.
Our mission is to cure all patients with histiocytic diseases and optimize outcomes through innovative and collaborative research.
- To develop a network for the advancement of clinical, translational, and basic research in histiocytic diseases.
- To advance therapeutic, etiological and mechanistic research through the implementation of high impact clinical trials and organized collection of well annotated clinical data and biology specimens.
- To define the pathogenesis of histiocytic diseases and develop risk-stratification strategies with tissue samples from patients treated on NACHO trials.
Consortium Principle Investigators
Carlos Rodriguez-Galindo, MD
Carl Allen, MD, PhD